Additional file 8: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Connock, Martin; Armoiry, Xavier; Tsertsvadze, Alexander; Melendez-Torres, G.; Royle, Pamela; Andronis, Lazaros; Clarke, Aileen

doi:10.6084/m9.figshare.8045564.v1

Additional file 8: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

journal contribution

posted on 2019-04-25, 05:00 authored by Martin Connock, Xavier Armoiry, Alexander Tsertsvadze, G. Melendez-Torres, Pamela Royle, Lazaros Andronis, Aileen Clarke

Association of survival estimates and reported medians and hazard ratios. (DOCX 32 kb)

History

Usage metrics

Keywords

Advanced NSCLC Licensed drugs Targeted therapies Immunotherapies Check point inhibitors

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 8: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

History

Usage metrics

Categories

Keywords

Licence

Exports